InvestorsHub Logo
Followers 11
Posts 190
Boards Moderated 0
Alias Born 06/28/2017

Re: None

Tuesday, 10/26/2021 5:53:24 AM

Tuesday, October 26, 2021 5:53:24 AM

Post# of 17535
Aurinia Pharmaceuticals currently has no debt on its balance sheet!

Aurinia has been operating solely on its equity investment and has NO debt burden, unique among biotech startups. This is BIG Positive as it would greatly reduce the risk around any Big Pharma (BMY) or other BP/Biotech suiters investing in the early stage launch of Lupkynis lupus nephritis - a Blockbuster oral therapy.

$1.5 - $2 BILLION per year are the Reported estimated peak sales!!! A Blockbuster for Patients too.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News